Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab (Remicade) for insulin sensitivity and cardiovascular risk in insulin‑resistant obesity
2005-000181-39Phase 4Completed
- Sponsor
- Medical University of Graz
- Start
- Jul 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of infliximab in obesity, sponsored by Medical University of Graz. Primary endpoint: Change in fasting insulin levels. Started Jul 2005; status: completed.
02
Drugs
infliximab
03
Conditions
obesity
Beyond the preview
Go deeper on 2005-000181-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000181-39.